Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

MSK researchers report an underlying cause of COVID brain

One of the dozens of unusual symptoms that have emerged in COVID-19 patients is a condition that's informally called "COVID brain" or "brain fog."

9 Feb 2021

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Researchers in China have developed three SARS-CoV-2 nanoparticle vaccines, containing receptor-binding domain (RBD) trimer, S1 trimer, and ectodomain (ECD) trimer, respectively. To do this, they have used Ferritin nanoparticle self-assembly technology.

9 Feb 2021

Smell and taste loss symptoms associated with robust SARS-CoV-2 antibody response in new study

Researchers in Italy report a correlation between the loss of smell and taste and an observed persistence or rise in antibody levels at five months after infection.

9 Feb 2021

Inhibition of protein glycosylation successfully prevents SARS-CoV-2 infection in vitro

A new study provides direct evidence that the oligosaccharides attached to the viral surface spike protein are essential for viral infection, offering new approaches to preventive and therapeutic drugs.

9 Feb 2021

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

A new study describes the first case of anti-SARS-CoV-2 antibodies detected in the cord blood of an infant born to a mother immunized with the first dose of an mRNA COVID-19 vaccine three weeks earlier.

9 Feb 2021

Pfizer-BioNTech COVID-19 vaccine immune response in the elderly

In a recent medRxiv preprint publication, the team led by Professor Ravindra K. Gupta has assessed the real-world immune responses following the vaccination against the SARS-CoV-2. The team measured 1) IFN-gamma (interferon-gamma) T cell responses, 2) both total IgG Spike/ IgG Spike RBD (receptor binding domain) and 3) neutralizing antibody responses to Spike in sera.

8 Feb 2021

4th preclinical study for Novavax in non-human primates, tests SARS-CoV-2 variants

Researchers in the United States have identified specific immune correlates that might be key to ensuring that vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protects against not only disease, but also viral transmission and emerging variants.

8 Feb 2021

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine.

8 Feb 2021

Moderna's COVID-19 vaccine effective against emerging variants

Researchers have conducted a study showing that the Moderna mRNA-1273 vaccine effectively protects against recently emerged variants of SARS-CoV-2 – the agent that causes COVID-19.

8 Feb 2021

Bioengineered ankyrin compounds show high in vitro activity against SARS-CoV-2 mutants

A new study describes the use of DARPin (designed ankyrin repeat proteins) therapeutic agents, each of which contains three different DARPin domains within the same molecule.

8 Feb 2021

Could graphene be an effective antiviral platform against SARS-CoV-2?

The urgent need for novel therapeutics has spurred investigation into broad-spectrum inhibitors of viral infection and replication. A new study describes the antiviral activity of synthesized graphene platforms, pointing to new therapeutic approaches against this virus.

8 Feb 2021

SARS-CoV-2 escape mutations identified against monoclonal antibodies and polyclonal immune sera

A recent study describes the experimental selection of SARS-CoV-2 mutants associated with resistance to antibodies, with important implications for vaccine development and therapeutic antibody use.

8 Feb 2021

COVID-19 pandemic and nanotechnology

Writing in the International Journal of Nanomedicine, Professor Dongki Yang, from the Department of Physiology, Gachon University, South Korea, has reviewed the available knowledge on the coronaviruses, current approaches to tackle the newly emerged SARS-CoV-2 infection, and the innovative application of nanotechnology in the COVID-19 pandemic.

8 Feb 2021

Gut fungi teach the immune system how to respond to their dangerous relatives

Common fungi, often present in the gut, teach the immune system how to respond to their more dangerous relatives, according to new research from scientists at Weill Cornell Medicine. Breakdowns in this process can leave people susceptible to deadly fungal infections.

7 Feb 2021

Orthodox Jewish in UK disproportionately impacted by COVID-19

Researchers have conducted a study showing an extremely high prevalence of severe acute respiratory coronavirus disease 2 (SARS-CoV-2) within a strictly Orthodox Jewish community in the UK.

7 Feb 2021

Targeted pulses of ultrasound can help treat a range of brain diseases

Ultrasound is not only used as an imaging technique but targeted pulses of ultrasound can be used as a highly accurate treatment for a range of brain diseases, for which there were previously only limited treatment options.

5 Feb 2021

Natural reinfection with respiratory syncytial virus varies based on antibody response

Researchers at Baylor College of Medicine found that while most individuals responded to respiratory syncytial virus (RSV) natural reinfection with a typical sustained antibody response associated with protection, a few individuals surprisingly responded atypically, not being able to sustain the antibody response, which declined to levels that made the individuals susceptible to RSV reinfection.

5 Feb 2021

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

A new preprint research paper posted to the bioRxiv server reports the development of highly effective neutralizing nanobodies targeting the viral receptor-binding domain (RBD), thus disrupting its engagement with the host cell angiotensin-converting enzyme 2 (ACE2) receptor.

4 Feb 2021

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Among these is the B.1.1.7 SARS-CoV-2 variant, with its characteristic N501Y mutation. A new preprint on the bioRxiv server reports the impact of this mutation on CD4 T cell responses, including antigen presentation on cells expressing Major Histocompatibility Complex (MHC) class II molecules.

4 Feb 2021

Study: Only 14% of the Bernese population developed antibodies against SARS-CoV-2

In the canton of Bern, only 14% of the adult population were infected with the coronavirus and developed antibodies against SARS-CoV-2.

4 Feb 2021

Antibody News and Research

Further Reading

MSK researchers report an underlying cause of COVID brain

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Smell and taste loss symptoms associated with robust SARS-CoV-2 antibody response in new study

Inhibition of protein glycosylation successfully prevents SARS-CoV-2 infection in vitro

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

Pfizer-BioNTech COVID-19 vaccine immune response in the elderly

4th preclinical study for Novavax in non-human primates, tests SARS-CoV-2 variants

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

Moderna's COVID-19 vaccine effective against emerging variants

Bioengineered ankyrin compounds show high in vitro activity against SARS-CoV-2 mutants

Could graphene be an effective antiviral platform against SARS-CoV-2?

SARS-CoV-2 escape mutations identified against monoclonal antibodies and polyclonal immune sera

COVID-19 pandemic and nanotechnology

Gut fungi teach the immune system how to respond to their dangerous relatives

Orthodox Jewish in UK disproportionately impacted by COVID-19

Targeted pulses of ultrasound can help treat a range of brain diseases

Natural reinfection with respiratory syncytial virus varies based on antibody response

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Study: Only 14% of the Bernese population developed antibodies against SARS-CoV-2

Event guide: Targeted Therapies Partnering & Licensing Summit Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo